Supplementary information

Effect and Mechanism of Oritavancin on hIAPP Amyloid Formation

Sheng-Nan Wang[1], Xin-Yu Li[1], Zhong-Xia Lu[1], Lu-Xin Liu[1], Xuan-Ping Xu[1], Wen-Gong Yu[1,2,3], Xin-Zhi Lu[1*]

[1]Key Laboratory of Marine Drugs, Ministry of Education; School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.

[2]Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao 266200, China.

[3]Key Laboratory of Glycoscience &Glycotechnology of Shandong Province, Qingdao 266003, China

*To whom correspondence should be addressed: Tel/Fax: +86-53282032067; e-mail: luxinzhi@ouc.edu.cn (X.-Z. Lu)



Fig. S1 CD spectra of different concentrations of Ori at 195- 250 nm.



Fig. S2 The cytotoxic effect of Ori (0.5-5 μM) on cell viability in NIT-1 cells for 24 h. Data are shown as means ± SD, n = 3 in normal distribution (*p<0.05; **p< 0.01; ***p<0.001).

Table S1. Result of Vina docking parameters for hIAPP + Ori.

mode	affinity (kcal mol^{-1})
1	-6.3
2	-6.2
3	-6.2
4	-6.2
5	-6.2
6	-6.1
7	-6.0
8	-5.8
9	-5.8



Fig. S3 The original scanned image of the western blot for β-actin and Cleaved Caspase-3 in Figure 6D.



Fig. S4 The original scanned image of the western blot for β-actin and Caspase-3 in Figure 6D.

Table S2. Comparison of the inhibition efficiencies with Ori and several reported compounds.

Compounds	Max concentration		Min concentration		Ref
	Molar ratio*	Inhibition ratio	Molar ratio*	Inhibition ratio	
Cloridarol	1:5	55.6%	1:1	17.3%	[1]
Genistein	1:5	63.4%	1:1	52.1%	[2]
Tanshinones 1	1:1	~70%	1:0.25	~63%	[3]
Tanshinones 2	1:1	~69%	1:0.25	~60%	[3]
Silybin A	1:0.8	~50%	1:0.1	N/A	[4]
Silybin B	1:0.8	~60%	1:0.1	No effect	[4]
Flavonoids B	1:4	92%	1:1	N/A	[5]
Flavonoids Ba	1:4	71%	1:1	N/A	[5]
Flavonoids W	1:4	40%	1:1	N/A	[5]
Flavonoids O	1:4	42%	1:1	N/A	[5]
Salvianolic acid B	1:5	Almost complete inhibition	1:1	68%	[6]
Isoquinoline alkaloids CHE	1:5	84.4%	1:1	54.4%	[7]
Bleomycin	1:5	N/A	1:1	N/A	[8]
Tetracycline derivatives	1:5	N/A	1:1	N/A	[9]
Teicoplanin	1:1	~71%	1:0.5	No effect	This work
Dalbavancin	1:1	~73%	1:0.5	No effect	This work
Oritavancin	1:1	Almost complete inhibition	1:0.01	36%	This work

*: Molar ratio=hIAPP/compounds

Reference

[1] Tang, Y., et al., *Repurposing a Cardiovascular Disease Drug of Cloridarol as hIAPP Inhibitor.* ACS Chemical Neuroscience, 2021. **12**(8): p. 1419-1427.

[2] Ren, B., et al., *Genistein: A Dual Inhibitor of Both Amyloid β and Human Islet Amylin Peptides.* ACS Chemical Neuroscience, 2018. **9**(5): p. 1215-1224.

[3] Ren, B., et al., *Tanshinones inhibit hIAPP aggregation, disaggregate preformed hIAPP fibrils, and protect cultured cells.* Journal of Materials Chemistry B, 2018. **6**(1): p. 56-67.

[4] García-Viñuales, S., et al., *Silybins inhibit human IAPP amyloid growth and toxicity through stereospecific interactions.* Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2022. **1870**(5).

[5] Wang, Y., et al., *Inhibitory activities of flavonoids from Scutellaria baicalensis Georgi on amyloid aggregation related to type 2 diabetes and the possible structural requirements for polyphenol in inhibiting the nucleation phase of hIAPP aggregation.* International Journal of Biological

Macromolecules, 2022. **215**: p. 531-540.

[6] Cheng, B., et al., *Salvianolic acid B inhibits the amyloid formation of human islet amyloid polypeptideand protects pancreatic beta-cells against cytotoxicity.* Proteins: Structure, Function, and Bioinformatics, 2012. **81**(4): p. 613-621.

[7] Wang, Y., et al., *Exploration of Isoquinoline Alkaloids as Potential Inhibitors against Human Islet Amyloid Polypeptide.* ACS Chemical Neuroscience, 2022. **13**(14): p. 2164-2175.

[8] Kumari, A., et al., *Bleomycin modulates amyloid aggregation in β-amyloid and hIAPP.* RSC Advances, 2020. **10**(43): p. 25929-25946.

[9] Xu, J., et al., *Tetracycline derivatives resist the assembly behavior of human islet amyloid polypeptide.* Biochimie, 2020. **174**: p. 95-106.